Compare BioNano Genomics Inc (BNGO) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Invesco S&P 500 Momentum ETF — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Invesco S&P 500 Momentum ETF trades at $153.04. The key difference: Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | SPMO | |
|---|---|---|
Market Cap | $13.20M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $4.92 | $161.66 |
52-Week Low | $1.09 | $107.84 |
Enterprise Value | $15.81M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
SPMO trades at $149.73, down 2.61% today, with a neutral technical signal. The ETF maintains a bullish moving average trend but faces resistance near $150. Recent news highlights strong momentum performance, gaining 7.5% in June 2026, driven by concentrated technology exposure and AI beneficiaries. A dividend of $0.25 is scheduled for June 2026.
Outlook remains positive with AI-driven growth potential, but risks include high volatility from sector concentration. Analyst sentiment is mixed, with some recommending buys for momentum exposure. Key support is at $149, with upside resistance at $151-$153.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
